Ixazomib and dexamethasone in high risk smoldering multiple myeloma: a clinical and correlative pilot study

"Ixazomib and dexamethasone in high risk smoldering multiple myeloma: a clinical and correlative pilot study." Leukemia & Lymphoma, 63(11), pp. 2760–2761

View correction statement:

Correction

Correction Statement

This article was originally published with errors, which have now been corrected in the online version. Please see Correction (http://dx.doi.org/10.1080/10428194.2022.2115252)

Disclosure statement

Hani Hassoun Dr. Hassoun has received research funding from Janssen and Nerviano and has received consulting fees from Novartis. Malin Hultcrantz Dr. Hultcrantz has received research funding from the Swedish Blood Cancer Foundation, the Karolinska Institute Foundations, GSK, Amgen, and Daiichi Sankyo. Dr. Hultcrantz serves in the Scientific advisory committee: GSK; and Consultancy: Curio Science LLC, Intellisphere LLC Neha Korde Dr. Korde has received research funding from: Amgen, Janssen; Honoraria: Medimmune; Consulting: CCO, PER, Cancer Network. Oscar Lahoud Dr. Lahoud served on the Advisory Board for MorphoSys. C. Ola Landgren Dr. Landgren has received research funding from the National Institutes of Health, the National Cancer Institute, the US Food and Drug Administration, the Multiple Myeloma Research Foundation, the International Myeloma Foundation, the Leukemia and Lymphoma Society, the Perelman Family Foundation, the Rising Tide Foundation, Amgen, Celgene, Janssen, Takeda, Glenmark, Seattle Genetics, and Karyopharm. Dr. Landgren has received honoraria from serving on advisory boards for Adaptive, Amgen, Binding Site, Bristol Myers Squibb, Celgene, Cellectis, Glenmark, Janssen, Juno, and Pfizer; and serving on Takeda, Merck, Janssen, and Theradex independent data monitoring committees outside the submitted work. Alexander Lesokhin Dr. Lesokhin has received honoraria from Genmab, Amgen, Bristol-Myers Squibb, and Janssen. Dr. Lesokhin has served on an advisory panel for Trillium Therapeutics, Pfizer, and Bristol-Myers Squibb; Has received research funding from Janssen Oncology, Trillium Therapeutics, Genentech, Bristol-Myers Squibb, Sanofi, Pfizer; Has patents/royalties from Serametrix, Inc. Sham Mailankody Dr. Mailankody has received research funding from Allogene Therapeutics, Takeda Oncology, Juno Therapeutics, Bristol Myers Squibb, Janssen Oncology, Fate Therapeutics. Dr. Mailankody has served on an advisory panel for Legend Biotech, Evicore, Janssen Oncology, BioAscend; Has received honoraria from Plexus Communication, OncLive, Physician Education Resource. Meghan Salcedo Urvi Shah Dr. Shah has received grants and research support from Celgene/Bristol Myers Squibb, Janssen paid to the institution, honorarium from Janssen and Physicians Education Resource, all outside of the submitted work. Eric Smith Dr. Smith serves in BMS: Patents/royalties, scientific advisory board; Sanofi: Patents/royalties; Novartis: Scientific advisory board; and Chimeric Therapeutics: Scientific advisory board. Carlyn Rose Tan Dr. Tan has received consulting fees from Janssen. Elizabeth Tavitian

Additional information

Funding

Funding support for this publication was provided by the Takeda Oncology and Memorial Sloan Kettering Core Grant [P30 CA008748].